Akrimax picks up major manufacturing contract

ROUSES POINT - Akrimax Pharmaceuticals has signed a major contract which is expected to bring work to its facility in the village of Rouses Point.

In announcement released by Akrimax Dec. 29, the corporation stated a manufacturing agreement for the production of pharmaceutical products for a global company will begin in 2009. Akrimax was reportedly selected from several potential partners in a competitive process for the contract, from the unnamed manufacturer.

Akrimax president Alan L. Rubino issued a statement in which he said the agreement "further validates Akrimax's decision to acquire the Rouses Point facility which possesses, diverse manufacturing and packaging capabilities, and a spotless regulatory and safety record."

"We are pleased to announce this development as we are ahead of our planned schedule of bringing in new manufacturing partnerships to our Rouses Point facility," he stated. "Our contract manufacturing partnership enhances our strategic plan and showcases the quality of our people and our ability to execute at this facility."

Rubino further stated the company is "proving every day that Made in America pharmaceutical manufacturing is good business for our partners because of our high-quality manufacturing, competitive value and excellent track record with the FDA."

Timothy Soule, Akrimax vice president of human resources and government affairs, said his corporation could not disclose further details of the contract, including the name of manufacturer and the length and other terms of the agreement, but said it was a "significant win" for Akrimax.

"We felt it was important to let the people of the North Country know about this agreement. We're very pleased," said Soule.

The news came as a pleasant surprise to Garry F. Douglas, president of the Plattsburgh-North Country Chamber of Commerce.

Douglas and the chamber of commerce have been credited for playing a pivotal role in bringing Akrimax to the village following the 2006 announcement by Wyeth Pharmaceuticals it would cease operations at its drug product manufacturing and packaging plant. Almost immediately following the announcement, the chamber of commerce began working with local and state agencies to find a new employer to take the place of Wyeth, which it successfully announced with Akrimax's acquisition of the facility last January.

Vote on this Story by clicking on the Icon


Use the comment form below to begin a discussion about this content.

Sign in to comment